SecBot SecBot
Biotech Drug Report Generated Oct 27, 2026

pelabresib

NVS·NOVARTIS AG
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3
Time to market
EU submission completed in Q3 2026; potential EU approval in 2027-2028. US/Japan/China filings delayed pending additional Phase 3 data, launch estimated 2027 or later per Novartis CEO.
Why 3/10
No near-term binary catalyst is scheduled. The EU submission was completed in Q3 2026 (a regulatory filing, not a dated decision), and the next hard catalyst would be an EMA decision ~12-18 months out. Pelabresib is a minor pipeline asset for Novartis, a ~$300B+ diversified pharma company with dozens of marketed drugs.
Actionable Insight NEUTRAL

The next catalyst is the EU regulatory decision on pelabresib for myelofibrosis, following the Q3 2026 submission, a typical EMA review takes 12-18 months, so a decision could come in late 2027 or 2028. The ongoing MANIFEST-3 Phase 3 trial (NCT07357727) started May 2026 with 460 patients and completion expected December 2030; interim safety data will be critical to resolving the AML transformation signal. For Novartis, even a positive EU approval would be a modest contributor given the company's diversified portfolio.

Price Chart

Loading chart...

Executive Summary

Pelabresib (CPI-0610/DAK539) is an investigational oral BET inhibitor being developed by Novartis (NVS) for myelofibrosis, a rare blood cancer. The Phase 3 MANIFEST-2 trial met its primary endpoint (66% vs 35% spleen volume reduction, p<0.001), but a safety signal, an imbalance in malignant transformations to acute myeloid leukemia, emerged post-acquisition, causing Novartis to delay US regulatory filings by years and take an $800M impairment on its $2.9B MorphoSys buyout. Novartis completed an EU submission in Q3 2026, but US/Japan/China filings await additional Phase 3 data from a new trial (MANIFEST-3) that began enrolling in May 2026. For Novartis, a ~$300B+ diversified pharma giant, pelabresib is a minor pipeline asset with no near-term binary catalyst.

How It Works

Pelabresib is a pill that inhibits BET proteins, which act as 'master switches' that turn on genes involved in inflammation and cancer growth in myelofibrosis. By blocking these proteins, the drug aims to reduce spleen enlargement, improve symptoms, and potentially modify the course of the disease when combined with the standard therapy ruxolitinib (Jakafi).

Trial Status

The pivotal Phase 3 MANIFEST-2 trial (NCT04603495) met its primary endpoint: 66% of patients on pelabresib + ruxolitinib achieved ≥35% spleen volume reduction at week 24 vs 35% on placebo + ruxolitinib (p<0.001). 96-week follow-up data showed durable responses. However, a safety signal involving an imbalance in malignant transformations to acute myeloid leukemia emerged, prompting Novartis to delay US filings. A new Phase 3 trial (MANIFEST-3, NCT07357727) began enrolling 460 patients in May 2026, expected to complete by December 2030. An extension study (NCT06401356) is also recruiting.

The Two-Sided Case

▲ Bull Case5
Phase 3 MANIFEST-2 met its primary endpoint with high statistical significance (66% vs 35% spleen response, p<0.001), demonstrating clear efficacy
96-week follow-up data showed durable and deepening responses in spleen volume, symptoms, and anemia
EU submission completed in Q3 2026, marking the first regulatory filing for the drug
Large unmet need in frontline myelofibrosis, current JAK inhibitors provide limited depth and durability of response
Novartis remains committed to the program despite the safety setback
▼ Bear Case5
Safety signal, imbalance in malignant transformations to acute myeloid leukemia in pelabresib-treated patients, caused Novartis to delay US/Japan/China filings by years
Novartis took an $800M impairment on the $2.9B MorphoSys acquisition, signaling reduced confidence in the asset's value
A new Phase 3 trial (MANIFEST-3) was required, pushing potential US approval to 2027 or later
Multiple JAK inhibitors already approved for myelofibrosis (ruxolitinib, fedratinib, pacritinib, momelotinib) create a competitive landscape
For Novartis, pelabresib is a tiny fraction of pipeline value, even full approval would have minimal impact on NVS stock

Upcoming Catalysts

  • EU regulatory decision on pelabresib for myelofibrosis (submitted Q3 2026; decision expected late 2027-2028)
  • MANIFEST-3 Phase 3 trial (NCT07357727) interim data readouts (trial started May 2026, completion Dec 2030)
  • Potential US/Japan/China regulatory filings pending additional safety data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 11

Hover a chip for the title
1 en.wikipedia.org2 fiercebiotech.com3 reuters.com4 nature.com5 ashpublications.org6 novartis.com7 novartis.com8 novartis.com9 myelofibrosisnews.com10 biomednexus.com11 deepnewz.com